Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancer.
In 2014, the size of the global biosimilar monoclonal antibodies market was valued over USD 352 million. While in 2015, the market size reaches USD xxx.x million. The global biosimilar monoclonal antibodies market is projected to grow with a CAGR between 42.9% and 43.5% during 2016-2022 and reach USD xxxx.x million by 2022.
Patient expiration of biologics, innovative product in the pipeline and increasing healthcare infrastructure are expected to be key factors driving the growth of global biosimilar monoclonal antibodies market. However, unfavorable government regulations and development policies, undesirable manufacturing process and cost structure associated with the manufacturing process are considered to be restraining factors in the global biosimilar monoclonal antibodies market. Furthermore, increasing demand for cost effective treatment, collaboration with the local players and high profitability in the market are the key opportunities for the companies to invest in the biosimilar monoclonal antibodies market.
The report segments the global biosimilar monoclonal antibodies market by drug class and by application. The biosimilar monoclonal antibodies market is driven by rituximab and infliximab submarkets, the rituximab submarket is accounted as the highest holding market share submarket and the infliximab submarket will become the leading submarket by 2018 continuing its dominance until 2022. The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab. Moreover, based on application the biosimilar monoclonal antibodies market is segmented into oncology, chronic and auto immune diseases, growth hormone deficiency and infectious diseases.
Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, Latin America, and Rest of the World (RoW). Europe is the largest biosimilar monoclonal antibodies market globally. Due to favorable regulatory policies designed by the European Medical Association (EMA) and since Europe was the first region to draft guidelines for approval of biosimilar products, the European market has a largest market share on the market.
Asia pacific is expected to grow at the highest CAGR over the forecast period and provides the opportunity to market growth due to increasing demand of cost effective treatment to the prevalence of chronic diseases, launch of new biosimilar monoclonal antibodies. Nevertheless, government investment in healthcare will also act as a growth opportunity for biosimilar monoclonal antibodies market Asia pacific region.
The companies covered in the report include Pfizer, Inc., Novartis AG, Reliance Life Sciences, Allergan plc, Coherus BioSciences, Inc., Biocon, Dr. Reddy's Laboratories Ltd., Boehringer Ingelheim GmbH, BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, BIOCAD, Genor BioPharma Co. Ltd, Celltrion, Inc.
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of biosimilars monoclonal antibodies globally as well as regionally. Moreover, the Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider.
The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of biosimilar monoclonal antibodies market. Moreover, the study highlights current market trends and provides forecast from 2016 to 2022. We also have highlighted future trends in the biosimilar monoclonal antibodies market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players.
Additionally, the analysis highlights rise and fall in the market shares of the key players in the market. This report will help manufacturers, suppliers and distributors of the biosimilar monoclonal antibodies market to understand the present and future trends in this market and formulate their strategies accordingly.
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches
2. Executive Summary
3. Biosimilar Monoclonal Antibodies Market Overview
3.2 Market Dynamics
3.7 Porter’s Five Forces Analysis
3.8 Growth Matrix Analysis
3.9 Competitive Landscape in the Biosimilar Monoclonal Antibodies Market
4. Global Biosimilar Monoclonal Antibodies Market, by Drug Class, (USD Million) 2014-2022
5. Global Biosimilar Monoclonal Antibodies Market, by Application, (USD Million) 2014-2022
5.3 Chronic and Autoimmune Diseases
5.4 Growth Hormone Deficiency
5.5 Infectious Diseases
6. Global Biosimilar Monoclonal Antibodies Market, by Region, (USD Million) 2014-2022
6.2 North America
6.2.1 North America Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.2.2 North America Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.3.1 Europe Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.3.2 Europe Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.4.2 Asia Pacific Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.5 Latin America
6.5.1 Latin America Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.5.2 Latin America Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
6.6 Rest of the World
6.6.1 RoW Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.6.2 RoW Biosimilar Monoclonal Antibodies Market, by Application (USD Million)
7. Leading Companies
7.1 Company Profiles
7.1.1 Pfizer, Inc.
7.1.2 Novartis AG
7.1.3 Reliance Life Sciences
7.1.4 Allergan plc
7.1.5 Coherus BioSciences, Inc.
7.1.7 Dr. Reddy's Laboratories Ltd.
7.1.8 Boehringer Ingelheim GmbH
7.1.9 BioXpress Therapeutics SA
7.1.10 Intas Pharmaceuticals Limited
7.1.12 Genor BioPharma Co. Ltd
7.1.13 Celltrion, Inc.
- Allergan plc
- BioXpress Therapeutics SA
- Boehringer Ingelheim GmbH
- Celltrion, Inc.
- Coherus BioSciences, Inc.
- Dr. Reddy's Laboratories Ltd.
- Genor BioPharma Co. Ltd
- Intas Pharmaceuticals Limited
- Novartis AG
- Pfizer, Inc.
- Reliance Life Sciences